Translational Drug Development (TD2) is a world-class drug development service, specializing in getting the newest and best oncology treatments to cancer patients as quickly as possible.

This is our Mission

To focus cutting edge science into translational solutions for our partners. Driven by science and motivated by patients, TD2 strives to make a significant impact on cancer.

This is our C.A.U.S.E.

We help companies identify patient populations most likely to respond to their compounds and we help discover every avenue to shorten development timelines, while ensuring new drugs are effective and safe.

Our proven techniques not only benefit patients, but also enable our clients to achieve measurable clinical responses, thereby creating meaningful value especially in the critical early phases of product development.

This is the TD2 Solution

Our unique approach integrates clinical and regulatory expertise with a deep understanding of science to "de-risk" the development process. Our "de-risk" approach involves a suite of tools built around cellular pathway interrogation, combination strategies, and the identification of specific contexts to uncover which new agents will have the greatest chance of success. We believe the future of oncology drug development depends on accurately defining specific genetic mutations, identifying their causes and effects, conferring sensitivity and resistance to new agents, and aligning that with clinical patient selection.

The TD2 team identifies every opportunity for our client's oncology agents to successfully navigate the regulatory maze and enable beneficial new drugs to reach market.

Let us apply our TD2 Solution to your oncology drug program.